Details for New Drug Application (NDA): 020997
✉ Email this page to a colleague
The generic ingredient in CHIROCAINE is levobupivacaine hydrochloride. Additional details are available on the levobupivacaine hydrochloride profile page.
Summary for 020997
Tradename: | CHIROCAINE |
Applicant: | Purdue Pharma Lp |
Ingredient: | levobupivacaine hydrochloride |
Patents: | 0 |
Formulation / Manufacturing: | see details |
Profile for product number 001
Active Rx/OTC/Discontinued: | DISCN | Dosage: | INJECTABLE;INJECTION | Strength | EQ 2.5MG BASE/ML **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | ||||
Approval Date: | Aug 5, 1999 | TE: | RLD: | No |
Profile for product number 002
Active Rx/OTC/Discontinued: | DISCN | Dosage: | INJECTABLE;INJECTION | Strength | EQ 5MG BASE/ML **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | ||||
Approval Date: | Aug 5, 1999 | TE: | RLD: | No |
Profile for product number 003
Active Rx/OTC/Discontinued: | DISCN | Dosage: | INJECTABLE;INJECTION | Strength | EQ 7.5MG BASE/ML **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | ||||
Approval Date: | Aug 5, 1999 | TE: | RLD: | No |
Expired US Patents for NDA 020997
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
Purdue Pharma Lp | CHIROCAINE | levobupivacaine hydrochloride | INJECTABLE;INJECTION | 020997-003 | Aug 5, 1999 | ⤷ Try a Trial | ⤷ Try a Trial |
Purdue Pharma Lp | CHIROCAINE | levobupivacaine hydrochloride | INJECTABLE;INJECTION | 020997-001 | Aug 5, 1999 | ⤷ Try a Trial | ⤷ Try a Trial |
Purdue Pharma Lp | CHIROCAINE | levobupivacaine hydrochloride | INJECTABLE;INJECTION | 020997-002 | Aug 5, 1999 | ⤷ Try a Trial | ⤷ Try a Trial |
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Complete Access Available with Subscription